secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001731122-24-001838
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax appoints Usama Chaudhry as CFO under independent contractor agreement
----------------------------------------------------------------------------

- Appointment effective November 18, 2024; Chaudhry to oversee financial reporting, budgeting, compliance.
- Annual fee of $180,000 payable in monthly installments; reasonable pre-approved expenses reimbursed.
- Chaudhry holds a Bachelor of Commerce in accounting from University of Northern British Columbia.
- Agreement is with Chaudhry U Consulting Inc.; Chaudhry remains independent contractor.
- Agreement includes 12-month post-termination non-compete and non-solicitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001838/0001731122-24-001838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000173112224001838/e6160_8k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-24-001838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer